Barclays reiterated coverage of Apple with a rating of Underweight and set a new price target of $173.00 from $197.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2025 | Buy → Hold | Needham | |
| 5/2/2025 | $290.00 → $275.00 | Buy | TD Cowen |
| 5/2/2025 | $217.00 | Buy → Neutral | Rosenblatt |
| 5/2/2025 | $170.62 | Hold → Underperform | Jefferies |
| 5/2/2025 | $260.00 → $245.00 | Buy | Monness Crespi & Hardt |
| 4/30/2025 | $197.00 → $173.00 | Underweight | Barclays |
| 4/30/2025 | $230.00 → $215.00 | Hold | Loop Capital |
| 4/29/2025 | $220.00 → $235.00 | Overweight | Morgan Stanley |
4 - Apple Inc. (0000320193) (Issuer)
4 - Apple Inc. (0000320193) (Issuer)
4 - Apple Inc. (0000320193) (Issuer)
8-K - Apple Inc. (0000320193) (Filer)
FWP - Apple Inc. (0000320193) (Subject)
10-Q - Apple Inc. (0000320193) (Filer)
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea